What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

Jemal, 2005, Cancer statistics, 2005, CA Cancer J Clin, 55, 10, 10.3322/canjclin.55.1.10

1986, Staging Announcement: FIGO Cancer Committee, Gynecol Oncol, 25, 383, 10.1016/0090-8258(86)90092-2

Ozols, 2003, Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study, J Clin Oncol, 21, 3194, 10.1200/JCO.2003.02.153

Bristow, 2002, Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis, J Clin Oncol, 20, 1248, 10.1200/JCO.20.5.1248

Hoskins, 1994, The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma, Am J Obstet Gynecol, 170, 974, 10.1016/S0002-9378(94)70090-7

Omura, 1991, Long follow-up and prognostic factor analysis in advanced ovarian carcinoma: the gynecologic oncology group experience, J Clin Oncol, 9, 1138, 10.1200/JCO.1991.9.7.1138

Hoskins, 1994, Epithelial ovarian carcinoma: principles of primary surgery, Gynecol Oncol, 55, S91, 10.1006/gyno.1994.1346

Makar, 1995, The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer, Gynecol Oncol, 56, 175, 10.1006/gyno.1995.1027

Le, 1997, Does debulking surgery improve survival in biologically aggressive ovarian carcinoma?, Gynecol Oncol, 67, 208, 10.1006/gyno.1997.4839

Eisenkop, 1998, Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study, Gynecol Oncol, 69, 103, 10.1006/gyno.1998.4955

Bristow, 2001, Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator, Gynecol Oncol, 83, 39, 10.1006/gyno.2001.6344

Eisenkop, 2003, Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study, Gynecol Oncol, 90, 390, 10.1016/S0090-8258(03)00278-6

Serov, 1973, Histologic typing of ovarian tumors, 17

Chi, 2004, Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach, Gynecol Oncol, 94, 650, 10.1016/j.ygyno.2004.01.029

Kaplan, 1958, Nonparametric estimator from incomplete observations, J Am Stat Assoc, 53, 457, 10.2307/2281868

Mantel, 1966, Evaluation of survival data and two new rank order statistics arising in its consideration, Cancer Chemo Rep., 50, 163

Cox, 1972, Regression models and life tables, J R Stat B, 34, 187

Griffiths, 1975, Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma, Natl Cancer Inst Monogr, 42, 101

Hoskins, 1992, The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a gynecologic oncology group study, Gynecol Oncol, 47, 159, 10.1016/0090-8258(92)90100-W

Eisenkop, 2001, Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with “biological aggressiveness” and survival?, Gynecol Oncol, 82, 435, 10.1006/gyno.2001.6313

Levine, 2004, Gene expression profiling of advanced ovarian cancers to predict the outcome of primary surgical cytoreduction (abstract), ASCO Proc, 23, 454

Omura, 1986, A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma, Cancer, 57, 1725, 10.1002/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J

Benedetti Panici, 2005, Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial, J Natl Cancer Inst, 97, 560, 10.1093/jnci/dji102

Crawford, 2005, Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial, J Clin Oncol, 23, 8802, 10.1200/JCO.2005.02.1287

Bristow, 2001, Ablation of metastatic ovarian carcinoma with the argon beam coagulator: pathologic analysis of tumor destruction, Gynecol Oncol, 83, 49, 10.1006/gyno.2001.6354

Rose, 2004, Secondary surgical cytoreduction for a advanced carcinoma, N Engl J Med, 351, 2489, 10.1056/NEJMoa041125

Armstrong, 2006, Intraperitoneal cisplatin and paclitaxel in ovarian cancer, N Engl J Med, 354, 34, 10.1056/NEJMoa052985

Barakat, 2002, Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up, J Clin Oncol, 20, 694, 10.1200/JCO.20.3.694

Rubin, 1999, Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings, Obstet Gynecol, 93, 21, 10.1016/S0029-7844(98)00334-2

McCreath WA, Abu-Rustum NR, Venkatraman ES, Caceres A, Bier R, Huh J, et al. Identification of prognostic factors after positive second look surgery in epithelial ovarian carcinoma. Gynecol Oncol in press.

Prefontaine, 1994, Reproducibility of tumor measurements in ovarian cancer: a study of interobserver variability, Gynecol Oncol, 55, 87, 10.1006/gyno.1994.1253

Farias-Eisner, 1994, The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery, Gynecol Oncol, 55, 108, 10.1006/gyno.1994.1257